State of Wyoming Acquires 156,763 Shares of Ironwood Pharmaceuticals, Inc. $IRWD

State of Wyoming raised its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 76.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 362,407 shares of the biotechnology company’s stock after acquiring an additional 156,763 shares during the period. State of Wyoming’s holdings in Ironwood Pharmaceuticals were worth $475,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in Ironwood Pharmaceuticals in the second quarter valued at approximately $25,000. R Squared Ltd increased its holdings in shares of Ironwood Pharmaceuticals by 286.5% in the 2nd quarter. R Squared Ltd now owns 38,765 shares of the biotechnology company’s stock worth $28,000 after buying an additional 28,735 shares during the last quarter. Focus Partners Advisor Solutions LLC raised its position in shares of Ironwood Pharmaceuticals by 284.6% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 29,409 shares in the last quarter. Captrust Financial Advisors purchased a new stake in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at $32,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 2nd quarter worth $36,000.

Wall Street Analyst Weigh In

A number of research analysts recently commented on IRWD shares. Wells Fargo & Company increased their target price on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the company an “equal weight” rating in a research note on Monday, January 5th. Zacks Research upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. Citigroup upgraded Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 29th. Finally, Craig Hallum raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $3.68.

Ironwood Pharmaceuticals Price Performance

IRWD opened at $4.49 on Thursday. The stock’s 50 day simple moving average is $4.03 and its 200 day simple moving average is $2.42. Ironwood Pharmaceuticals, Inc. has a 1 year low of $0.53 and a 1 year high of $5.78. The firm has a market cap of $730.43 million, a price-to-earnings ratio of 28.06 and a beta of 0.17.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.15. Ironwood Pharmaceuticals had a negative return on equity of 15.17% and a net margin of 8.70%.The firm had revenue of $122.06 million during the quarter, compared to the consensus estimate of $74.22 million. As a group, sell-side analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.